A Randomized, Multicentre, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer
This study is an open label, randomized, multicentre trial of MM-302 plus trastuzumab. The
trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the
chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic
HER2-positive breast cancer patients. Patients may not have been previously treated with an
anthracycline in any setting. Patients must have received prior treatment with trastuzumab
in any setting, have either progressed or are intolerant to ado-trastuzumab emtansine in the
metastatic or locally advanced setting, have either progressed or are intolerant to
pertuzumab in the metastatic or locally advanced setting or had disease recurrence within 12
months of pertuzumab treatment in the neoadjuvant or adjuvant setting.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society